SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The index is trending amid volatility as traders weigh rising bond yields and geopolitical tensions against ongoing support from tech sector performance. Discussion remains fragmented, with bears focusing on a potential September correction while bulls anticipate continued momentum.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending amid ongoing debate over its long-term valuation, with investors weighing the company's significant contracted backlog and infrastructure buildout against macro-economic headwinds and market volatility. While some traders express frustration with the recent price consolidation, long-term investors emphasize strong fundamentals and the company's position as an AI data center builder.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

The discussion around SOXL is dominated by intense community frustration regarding the ETF's performance relative to its underlying semiconductor components, with many traders labeling it a 'scam' or 'rigged' due to perceived tracking errors and volatility. Investors are primarily focused on positioning ahead of upcoming Nvidia earnings and debating whether the current price action signals a deeper semiconductor correction or a potential bounce.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trading in a tight, range-bound pattern as traders weigh concerns over rising U.S. Treasury yields and geopolitical tensions against the resilience of mega-cap tech stocks. Market participants remain divided, with some betting on a seasonal September correction while others focus on continued institutional support for the AI sector.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is experiencing significant volatility and debate, with a recent collaboration update involving Panasonic and JANCTION sparking conflicting reactions. While some traders view the news as a positive catalyst for future utility and adoption, others remain skeptical, dismissing the project as a scam and pointing to poor price performance and lack of clear revenue impact.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors react to the company's autonomous vehicle progress, specifically the expansion of its Robotaxi fleet in Austin ahead of an upcoming product launch event. While bulls point to this momentum and robot-related developments as a positive catalyst, bears remain skeptical, framing the price action as a potential "sell the news" setup or an unsustainable speculative pump.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

SOXS is trending as traders debate the sustainability of the semiconductor sector's AI-driven rally, with many expressing bearish sentiment based on concerns over valuation, sector debt, and broader economic headwinds. Community sentiment remains polarized, with some traders actively shorting or buying the dip while others caution against the structural decay inherent in leveraged inverse ETFs.

Investment Managers Series Trust II - Tradr 2X Short NBIS Daily ETF

Tradr 2X Short NBIS Daily ETF

NBIZ is experiencing significant volatility as traders use the 2x leveraged inverse ETF to bet against NBIS, with the conversation dominated by intense debate over AI sector valuation, short-squeeze potential, and the risks of holding leveraged vehicles that suffer from volatility decay. While some traders report locking in profits from short-term price swings, others express frustration over the complex tracking of the fund during rapid market moves.

JinkoSolar Holding Co., Ltd. engages in the manufacture of solar modules. It distributes solar products and sells its solutions and services to a diversified international utility, commercial and residential customers. The company was founded by Xian De Li, Kang Ping Chen, and Xian Hua Li in June 2006 and is headquartered in Shangrao, China.

JinkoSolar Holding Co. Ltd - ADR

JinkoSolar Holding Co LTD

JinkoSolar is receiving significant attention from the community due to its low market capitalization relative to its high revenue, with many traders labeling the stock as undervalued and bullishly highlighting its 10% dividend and triple-AAA bankability rating. While some market participants express frustration over recent price declines, the discussion is dominated by arguments regarding the company's strong fundamentals versus perceived market suppression.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to positive Phase 3 clinical trial results for its LSD-based treatment in generalized anxiety disorder, which analysts indicate de-risks the company's lead asset and supports a multibillion-dollar commercial opportunity. While some traders debate the long-term scalability of in-clinic psychedelic therapy and the impact of a recent large equity offering, community sentiment remains largely bullish ahead of further trial results and anticipated regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer...

Ovid Therapeutics (OVID) to Release Earnings on Tuesday

Ovid Therapeutics (NASDAQ:OVID) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 6,957,013 shares, a decline of 25.5% from the March 31st total of 9,337,824 shares. Based on an average trading volume of...

Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts

Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are covering the firm, MarketBeat.com reports. One research...

Ovid Therapeutics' (OVID) "Outperform" Rating Reiterated at Wedbush

Wedbush reiterated an "outperform" rating and issued a $7.00 price target on shares of Ovid Therapeutics in a report on Wednesday...

Ovid Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. It discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. The company was founded by Matthew During and Jeremy M. Levin on April 1, 2014 and is headquartered in New York, NY.

Ovid Therapeutics Inc

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

OVID Ovid Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest OVID News